Literature DB >> 21617959

Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization.

Noriaki Shimada1, Kyoko Ohno-Matsui2, Kengo Hayashi1, Takeshi Yoshida1, Takashi Tokoro1, Manabu Mochizuki1.   

Abstract

PURPOSE: To determine the incidence and features of macular retinal detachment (RD) after successful intravitreal injection of bevacizumab (IVB) for the treatment of myopic choroidal neovascularizations (CNVs).
METHODS: Seventy-four eyes of 74 patients who received IVB for myopic CNV were studied. Fluorescein angiography (FA) and optical coherence tomography (OCT) were performed at baseline, at 1 week after IVB, and every month thereafter. The shortest follow-up period was 6 months.
RESULTS: Four eyes (5.4%) either developed or had increased macular RD after successful IVB. In the three eyes, macular RD newly developed 1 month after IVB despite the absence of dye leakage. The remaining eye had a limited area of macular RD at baseline and increased despite the disappearance of dye leakage from the CNV after the IVB. The four eyes that developed a macular RD had retinoschisis around the CNV before IVB, whereas none of the 70 other patients had a retinoschisis throughout the follow-up period. In all four eyes that either developed or had increased macular RD, outer lamellar holes were detected at the upper edge of the RD by OCT examinations, whereas none of the patients who did not develop a macular RD after IVB showed outer lamellar holes.
CONCLUSIONS: These results suggest that there is a risk of developing macular RD after IVB in eyes with myopic CNV. Periodic OCT examinations are recommended for patients with myopic CNV to search for RDs after IVB.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617959     DOI: 10.1007/s10384-011-0034-2

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  13 in total

1.  Ultrastructure of internal limiting membrane in myopic foveoschisis.

Authors:  Hajime Bando; Yasushi Ikuno; Jun-Sub Choi; Yasuo Tano; Ichiro Yamanaka; Tatsuro Ishibashi
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

2.  Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.

Authors:  Izumi Yamamoto; Adam H Rogers; Elias Reichel; Paul A Yates; Jay S Duker
Journal:  Br J Ophthalmol       Date:  2006-07-26       Impact factor: 4.638

3.  Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.

Authors:  W-M Chan; T Y Y Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2008-09-18       Impact factor: 4.638

4.  Macular complications associated with posterior staphyloma.

Authors:  S M Steidl; R C Pruett
Journal:  Am J Ophthalmol       Date:  1997-02       Impact factor: 5.258

5.  Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.

Authors:  H Sakaguchi; Y Ikuno; F Gomi; M Kamei; M Sawa; M Tsujikawa; Y Oshima; S Kusaka; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-16       Impact factor: 4.638

6.  Axial length measurements and fundus changes of the myopic eye.

Authors:  B J Curtin; D B Karlin
Journal:  Am J Ophthalmol       Date:  1971-01       Impact factor: 5.258

7.  Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.

Authors:  Magda Gharbiya; Rosalia Giustolisi; Francesca Allievi; Nicoletta Fantozzi; Luigi Mazzeo; Vittorio Scavella; Corrado Balacco Gabrieli
Journal:  Am J Ophthalmol       Date:  2010-03       Impact factor: 5.258

8.  Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2007-06-28       Impact factor: 12.079

9.  Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.

Authors:  Yasushi Ikuno; Kaori Sayanagi; Kaori Soga; Miki Sawa; Motokazu Tsujikawa; Fumi Gomi; Yasuo Tano
Journal:  Am J Ophthalmol       Date:  2008-09-06       Impact factor: 5.258

10.  Progression from macular retinoschisis to retinal detachment in highly myopic eyes is associated with outer lamellar hole formation.

Authors:  N Shimada; K Ohno-Matsui; T Yoshida; Y Sugamoto; T Tokoro; M Mochizuki
Journal:  Br J Ophthalmol       Date:  2008-06       Impact factor: 4.638

View more
  5 in total

1.  Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

Authors:  T Y Y Lai; F O J Luk; G K Y Lee; D S C Lam
Journal:  Eye (Lond)       Date:  2012-05-18       Impact factor: 3.775

Review 2.  Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection.

Authors:  Jianghui Wang; Zefeng Kang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-25       Impact factor: 3.117

3.  Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.

Authors:  Pedro Cuevas; Luis A Outeiriño; Carlos Azanza; Javier Angulo; Guillermo Giménez-Gallego
Journal:  Eur J Med Res       Date:  2012-07-12       Impact factor: 2.175

Review 4.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

Review 5.  The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.

Authors:  Edith Poku; John Rathbone; Ruth Wong; Emma Everson-Hock; Munira Essat; Abdullah Pandor; Allan Wailoo
Journal:  BMJ Open       Date:  2014-07-17       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.